Vinay Kapoor, MD
Endocrinology, Diabetes & Metabolism · Manhasset, NYNPI 1952491698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $736,272 of the $819,886 with a category attached, or 89.8%. 49 manufacturers reported payments, led by Novo Nordisk at 29.4% of the total. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,824 payments — averaging $449.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$241K
- Dexcom, Inc.$80K
- Johnson & Johnson$73K
- AstraZeneca$63K
- Amgen$59K
- Intuity Medical Inc$49K
- plus $254K from 43 others
What the payments were for
- Consulting fees$8,7731%
- Speaking & faculty fees$736,27290%
- Travel & lodging$18,5602%
- Food & beverage$56,1947%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$120,314
- Ozempic$98,743
- FARXIGA$59,352
- JARDIANCE$52,180
- Pogo Automatic Blood Glucose Monitoring System$48,872
- DEXCOM G7 GSS (161)$42,618
- Kerendia$42,328
- XARELTO$40,277
- TZIELD$37,544
- CeQur Simplicity$35,480
- TEPEZZA$32,738
- INVOKANA$31,180
- FREESTYLE LIBRE 3$18,175
- Repatha$17,706
- GVOKE HYPOPEN$17,440
- DEXCOM G6 TRANSMITTER$16,845
- DEXCOM STELO GLUCOSE BIOSENSOR$16,151
- FreeStyle Libre Pro$15,524
- STEGLATRO$14,350
- Tresiba$11,135
How this compares
$819,886 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 994 | $1,928,506 |
| FarxigaDapagliflozin Propanediol | 394 | $495,542 |
| Tresiba Flextouch U-200Insulin Degludec | 388 | $413,658 |
| JardianceEmpagliflozin | 315 | $395,262 |
| Xigduo XrDapaglifloz Propaned/Metformin | 324 | $383,975 |
| JanumetSitagliptin Phos/Metformin Hcl | 254 | $305,529 |
| SynjardyEmpagliflozin/Metformin Hcl | 130 | $176,957 |
| RybelsusSemaglutide | 90 | $169,551 |
| JanuviaSitagliptin Phosphate | 104 | $141,384 |
| KerendiaFinerenone | 98 | $118,013 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $103,410 |
| MounjaroTirzepatide | 49 | $79,979 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 66 | $79,887 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 132 | $79,658 |
| ProliaDenosumab | 42 | $73,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $241,245 | $2,127,1181,173 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta, Jentadueto | $39,588 | $695,029553 claims |
| AstraZenecaFarxiga | $63,152 | $495,542394 claims |
| MerckJanumet, Januvia, Janumet Xr | $15,118 | $464,104369 claims |
| Lilly USA, LLCMounjaro, Trulicity | $13,678 | $119,62174 claims |
| BayerKerendia | $43,071 | $118,01398 claims |
| AmgenProlia, Evenity (2 Syringes) | $59,233 | $102,44754 claims |
| AbbVieCreon, Synthroid, Linzess | $726 | $92,539255 claims |
| Johnson & JohnsonXarelto, Invokana | $72,918 | $57,84958 claims |
| Cequr CorporationCequr Simplicity | $35,557 | $52,309124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Manhasset
- Barbara HirschManhasset$746K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- John BilezikianNew York$809K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
- Erlin MarteBuffalo$570K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.